The adoption of CDK4/6 inhibitors into the management of breast cancer was underpinned by an awareness that alterations in the cyclin D1–CDK–Rb axis are associated with the development of hormone receptor (HR)-positive breast cancer, with CDK4/6 playing a pivotal role in driving malignant cell cycle progression. Here, CCND1 is linked to breast carcinoma.